Fairvalue-Calculator Fairvalue-Calculator
EN DE

Medigen Biotechnology Corp (3176) Fair Value & Analysis

Healthcare · TW · Market cap 4.7B TWD

Price33.15 TWD
Fair Value50.05 TWD
Upside+51.0%
Quality80/100
Evidence: Low Range 37.54 TWD – 62.57 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Medigen Biotechnology Corp (3176) currently trades at 33.15 TWD, while our model-based Fair Value estimate is 50.05 TWD — implying the stock looks roughly 51.0% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Medigen Biotechnology Corp (3176) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 50.05 TWD versus a price of 33.15 TWD — about +51% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 3176?
Our 21-model fair value for Medigen Biotechnology Corp is 50.05 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 33.15 TWD.
What is the quality score of 3176?
Medigen Biotechnology Corp has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.